Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank Disease ID
1 ADA [2] Purine metabolism, Primary immunodeficiency D11017 Elapegademase [1] 65
2 TNFRSF13C [1] Primary immunodeficiency D12151 Ianalumab [5] 35, 46, 49, 53, 95
3 IL2RG [4] Viral protein interaction with cytokine and cytokine receptor, Th1 and Th2 cell differentiation, Th17 cell differentiation, Primary immunodeficiency D00748 Aldesleukin [6] 2, 35, 49, 65, 96, 97
4 JAK3 [5] Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral carcinogenesis, Primary immunodeficiency D09970 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271
5 JAK3 [5] Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral carcinogenesis, Primary immunodeficiency D10653 Peficitinib [1] 46
6 LCK [5] Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Yersinia infection, Primary immunodeficiency D03658 Dasatinib [2] 51, 85
7 LCK [5] Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Yersinia infection, Primary immunodeficiency D06414 Dasatinib [2] 51, 85
8 BTK [1] Primary immunodeficiency D10223 Ibrutinib [3] 28, 60, 61
9 BTK [1] Primary immunodeficiency D10893 Acalabrutinib [2] 46, 61
10 BTK [1] Primary immunodeficiency D11422 Zanubrutinib [2] 300, 331
11 BTK [1] Primary immunodeficiency D11457 Fenebrutinib [1] 13
12 BTK [1] Primary immunodeficiency D11478 Branebrutinib [3] 46, 49, 53
13 BTK [1] Primary immunodeficiency D12160 Orelabrutinib [3] 13, 61, 63
14 CD3D [4] Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Primary immunodeficiency D05092 Muromonab [3] 60, 96, 97
15 CD3D [4] Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Primary immunodeficiency D06314 Visilizumab [2] 96, 97
16 CD3D [4] Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Primary immunodeficiency D08959 Otelixizumab [1] 46
17 CD3E [4] Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Primary immunodeficiency D05092 Muromonab [3] 60, 96, 97
18 CD3E [4] Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Primary immunodeficiency D06314 Visilizumab [2] 96, 97
19 CD3E [4] Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Primary immunodeficiency D08959 Otelixizumab [1] 46
20 CD3E [4] Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Primary immunodeficiency D11463 Mosunetuzumab [1] 49
21 CD19 [1] Primary immunodeficiency D11757 Inebilizumab [4] 11, 13, 51, 300
22 CD40 [6] Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Systemic lupus erythematosus, Primary immunodeficiency, Viral myocarditis D11357 Bleselumab [1] 222
23 CD40 [6] Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Systemic lupus erythematosus, Primary immunodeficiency, Viral myocarditis D11597 Ravagalimab [2] 53, 97
24 CD40 [6] Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Systemic lupus erythematosus, Primary immunodeficiency, Viral myocarditis D11610 Iscalimab [2] 49, 53
25 CD40LG [5] T cell receptor signaling pathway, Toxoplasmosis, Systemic lupus erythematosus, Primary immunodeficiency, Viral myocarditis D06193 Toralizumab [1] 63